126 related articles for article (PubMed ID: 9458331)
1. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes.
van Ark-Otte J; Samelis G; Rubio G; Lopez Saez JB; Pinedo HM; Giaccone G
Oncol Rep; 1998; 5(1):249-55. PubMed ID: 9458331
[TBL] [Abstract][Full Text] [Related]
2. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
3. Development of taxane resistance in a panel of human lung cancer cell lines.
Breen L; Murphy L; Keenan J; Clynes M
Toxicol In Vitro; 2008 Aug; 22(5):1234-41. PubMed ID: 18514476
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines.
Ikubo S; Takigawa N; Ueoka H; Kiura K; Tabata M; Shibayama T; Chikamori M; Aoe K; Matsushita A; Harada M
Anticancer Res; 1999; 19(5B):3985-8. PubMed ID: 10628341
[TBL] [Abstract][Full Text] [Related]
5. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
Yu D; Liu B; Jing T; Sun D; Price JE; Singletary SE; Ibrahim N; Hortobagyi GN; Hung MC
Oncogene; 1998 Apr; 16(16):2087-94. PubMed ID: 9572489
[TBL] [Abstract][Full Text] [Related]
7. Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
Yang CH; Wang C; Ojima I; Horwitz SB
J Nat Prod; 2018 Mar; 81(3):600-606. PubMed ID: 29517223
[TBL] [Abstract][Full Text] [Related]
8. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents.
Ihnat MA; Lariviere JP; Warren AJ; La Ronde N; Blaxall JR; Pierre KM; Turpie BW; Hamilton JW
Clin Cancer Res; 1997 Aug; 3(8):1339-46. PubMed ID: 9815817
[TBL] [Abstract][Full Text] [Related]
9. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.
Minderman H; Brooks TA; O'Loughlin KL; Ojima I; Bernacki RJ; Baer MR
Cancer Chemother Pharmacol; 2004 May; 53(5):363-9. PubMed ID: 15060738
[TBL] [Abstract][Full Text] [Related]
10. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
11. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
[TBL] [Abstract][Full Text] [Related]
12. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Ciardiello F; Caputo R; Pomatico G; De Laurentiis M; De Placido S; Bianco AR; Tortora G
Int J Cancer; 2000 Mar; 85(5):710-5. PubMed ID: 10699953
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
Shabbits JA; Mayer LD
Mol Cancer Ther; 2002 Jan; 1(3):205-13. PubMed ID: 12467215
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Kelland LR; Abel G
Cancer Chemother Pharmacol; 1992; 30(6):444-50. PubMed ID: 1356649
[TBL] [Abstract][Full Text] [Related]
15. [Microtubules and antineoplastic drugs].
Arioka H; Saijo N
Gan To Kagaku Ryoho; 1994 Apr; 21(5):583-90. PubMed ID: 7908790
[TBL] [Abstract][Full Text] [Related]
16. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.
Rabindran SK; He H; Singh M; Brown E; Collins KI; Annable T; Greenberger LM
Cancer Res; 1998 Dec; 58(24):5850-8. PubMed ID: 9865745
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
18. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin.
Yang X; Pagé M
Oncol Res; 1995; 7(12):619-24. PubMed ID: 8704279
[TBL] [Abstract][Full Text] [Related]
20. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
Hill BT; Whelan RD; Shellard SA; McClean S; Hosking LK
Invest New Drugs; 1994; 12(3):169-82. PubMed ID: 7896535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]